AR091218A1 - Agente terapeutico o agente profilactico para los trastornos cognitivos - Google Patents
Agente terapeutico o agente profilactico para los trastornos cognitivosInfo
- Publication number
- AR091218A1 AR091218A1 ARP130101907A AR091218A1 AR 091218 A1 AR091218 A1 AR 091218A1 AR P130101907 A ARP130101907 A AR P130101907A AR 091218 A1 AR091218 A1 AR 091218A1
- Authority
- AR
- Argentina
- Prior art keywords
- agent
- cognitive disorders
- amino acid
- profilactic
- therapeutic agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012124336 | 2012-05-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091218A1 true AR091218A1 (es) | 2015-01-21 |
Family
ID=49673425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101907 AR091218A1 (es) | 2012-05-31 | 2013-05-30 | Agente terapeutico o agente profilactico para los trastornos cognitivos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US20150183854A1 (https=) |
| EP (2) | EP2857039B1 (https=) |
| JP (3) | JP5971659B2 (https=) |
| KR (2) | KR102133610B1 (https=) |
| CN (1) | CN104602708B (https=) |
| AR (1) | AR091218A1 (https=) |
| AU (2) | AU2013268364B2 (https=) |
| BR (1) | BR112014029566A2 (https=) |
| CA (1) | CA2875205C (https=) |
| CY (1) | CY1122530T1 (https=) |
| DK (1) | DK2857039T3 (https=) |
| ES (2) | ES2973070T3 (https=) |
| HR (1) | HRP20192267T1 (https=) |
| HU (1) | HUE046919T2 (https=) |
| IL (1) | IL235899B (https=) |
| LT (1) | LT2857039T (https=) |
| ME (1) | ME03587B (https=) |
| MX (1) | MX361128B (https=) |
| MY (1) | MY172458A (https=) |
| NZ (1) | NZ630536A (https=) |
| PH (1) | PH12014502669B1 (https=) |
| PL (1) | PL2857039T3 (https=) |
| PT (1) | PT2857039T (https=) |
| RS (1) | RS59802B1 (https=) |
| RU (1) | RU2657438C2 (https=) |
| SG (2) | SG10201805410XA (https=) |
| SI (1) | SI2857039T1 (https=) |
| TW (2) | TWI700296B (https=) |
| WO (1) | WO2013180238A1 (https=) |
| ZA (1) | ZA201409186B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20120244174A1 (en) | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| JP6457263B2 (ja) * | 2011-05-20 | 2019-01-23 | オリゴメリックス インコーポレイテッド | タウプロテアーゼ組成物および使用方法 |
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| SG10201708959WA (en) | 2012-07-03 | 2017-11-29 | Univ Washington | Antibodies to tau |
| TWI734975B (zh) * | 2014-06-27 | 2021-08-01 | 美商Ｃ２Ｎ醫療診斷有限責任公司 | 人類化抗-tau抗體 |
| US20190224339A1 (en) * | 2016-04-29 | 2019-07-25 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| JP6785372B2 (ja) * | 2016-09-30 | 2020-11-18 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 多重特異性分子の機能分析のためのｓｐｒに基づく二重結合アッセイ |
| SG11201907422RA (en) | 2017-02-17 | 2019-09-27 | Denali Therapeutics Inc | Anti-tau antibodies and methods of use thereof |
| JP2018139530A (ja) | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
| AR112600A1 (es) | 2017-05-30 | 2019-11-20 | Teijin Pharma Ltd | Anticuerpo anti-receptor de igf-i |
| EP3691639B1 (en) | 2017-10-02 | 2023-11-15 | Merck Sharp & Dohme LLC | Chromane monobactam compounds for the treatment of bacterial infections |
| AU2018352308B2 (en) | 2017-10-16 | 2025-06-05 | Eisai R&D Management Co., Ltd. | Anti-tau antibodies and uses thereof |
| EP4471152A3 (en) | 2018-04-06 | 2025-03-26 | Teijin Pharma Limited | Spns2 neutralizing antibody |
| EP3819378A4 (en) | 2018-07-04 | 2022-09-14 | Aichi Medical University | OLIGONUCLEOTIDES FOR CONTROL OF TAU SPLICING AND THEIR USES |
| CN110028583B (zh) * | 2019-05-07 | 2020-09-11 | 温州医科大学 | 抗Tau抗体及其在治疗阿尔茨海默病、创伤性脑损伤中的应用 |
| GB2585252A (en) | 2019-07-05 | 2021-01-06 | Gen2 Neuroscience Ltd | Tau epitope and binding molecules |
| JP7429404B2 (ja) * | 2019-08-06 | 2024-02-08 | 慶應義塾 | タウ関連疾患モデルの製造方法 |
| US20220365102A1 (en) | 2019-09-30 | 2022-11-17 | Nipro Corporation | Tau protein detection method using blood sample as test specimen |
| IL296611A (en) * | 2020-03-19 | 2022-11-01 | Vascular Biosciences | Car peptide for improved coronavirus survival |
| CA3183835A1 (en) | 2020-06-25 | 2021-12-30 | Jeanne E. Baker | High affinity antibodies targeting tau phosphorylated at serine 413 |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| KR20250069606A (ko) | 2022-09-15 | 2025-05-19 | 보이저 테라퓨틱스, 인크. | 타우 결합 화합물 |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS587390B2 (ja) | 1975-03-11 | 1983-02-09 | ツキシマキカイ カブシキガイシヤ | ア−クヨウセツホウホウ |
| JP3587390B2 (ja) | 1994-03-17 | 2004-11-10 | タカラバイオ株式会社 | リン酸化アミノ酸誘導体及びリン酸化ペプチド合成方法 |
| US20020086009A1 (en) * | 1996-03-13 | 2002-07-04 | Koichi Ishiguro | Anti-phosphorylated tau protein antibodies and methods for detecting alzheimer`s disease with the use of the same |
| US20080199471A1 (en) * | 2002-03-01 | 2008-08-21 | Bernett Matthew J | Optimized cd40 antibodies and methods of using the same |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20070280935A1 (en) * | 2006-04-07 | 2007-12-06 | Bernd Bohrmann | Antibody that recognizes phosphorylated peptides |
| EP2028932A4 (en) * | 2006-06-16 | 2011-10-12 | Vitruvean Llc | TAU AND AMYLOID FOREIGNER FRAGMENT EXPRESSING TRANSGENIC FLY |
| UA107571C2 (xx) * | 2009-04-03 | 2015-01-26 | Фармацевтична композиція | |
| CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| US20120244174A1 (en) * | 2011-01-31 | 2012-09-27 | Intellect Neurosciences Inc. | Treatment of tauopathies |
| TR201102696U (tr) * | 2011-05-27 | 2011-06-21 | Turhal Sal�H | Bağlantısız hareketli ürün reklam standı. |
| PL2857039T3 (pl) * | 2012-05-31 | 2020-05-18 | Osaka City University | Środek terapeutyczny lub środek profilaktyczny na otępienie |
| JP2018139530A (ja) * | 2017-02-27 | 2018-09-13 | 帝人ファーマ株式会社 | 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤 |
-
2013
- 2013-05-30 PL PL13797290T patent/PL2857039T3/pl unknown
- 2013-05-30 CA CA2875205A patent/CA2875205C/en active Active
- 2013-05-30 ME MEP-2019-341A patent/ME03587B/me unknown
- 2013-05-30 US US14/403,803 patent/US20150183854A1/en not_active Abandoned
- 2013-05-30 CN CN201380040658.9A patent/CN104602708B/zh active Active
- 2013-05-30 TW TW102119176A patent/TWI700296B/zh active
- 2013-05-30 RS RS20191640A patent/RS59802B1/sr unknown
- 2013-05-30 AU AU2013268364A patent/AU2013268364B2/en active Active
- 2013-05-30 WO PCT/JP2013/065090 patent/WO2013180238A1/ja not_active Ceased
- 2013-05-30 PT PT137972907T patent/PT2857039T/pt unknown
- 2013-05-30 RU RU2014153099A patent/RU2657438C2/ru active
- 2013-05-30 AR ARP130101907 patent/AR091218A1/es active IP Right Grant
- 2013-05-30 HU HUE13797290A patent/HUE046919T2/hu unknown
- 2013-05-30 ES ES19207405T patent/ES2973070T3/es active Active
- 2013-05-30 DK DK13797290.7T patent/DK2857039T3/da active
- 2013-05-30 EP EP13797290.7A patent/EP2857039B1/en active Active
- 2013-05-30 MX MX2014014187A patent/MX361128B/es active IP Right Grant
- 2013-05-30 SG SG10201805410XA patent/SG10201805410XA/en unknown
- 2013-05-30 MY MYPI2014703534A patent/MY172458A/en unknown
- 2013-05-30 KR KR1020147035417A patent/KR102133610B1/ko active Active
- 2013-05-30 JP JP2014518734A patent/JP5971659B2/ja active Active
- 2013-05-30 ES ES13797290T patent/ES2763361T3/es active Active
- 2013-05-30 BR BR112014029566A patent/BR112014029566A2/pt not_active Application Discontinuation
- 2013-05-30 NZ NZ630536A patent/NZ630536A/en unknown
- 2013-05-30 TW TW109121902A patent/TWI777183B/zh active
- 2013-05-30 EP EP19207405.2A patent/EP3662931B1/en active Active
- 2013-05-30 LT LTEP13797290.7T patent/LT2857039T/lt unknown
- 2013-05-30 SG SG11201407878VA patent/SG11201407878VA/en unknown
- 2013-05-30 HR HRP20192267TT patent/HRP20192267T1/hr unknown
- 2013-05-30 KR KR1020207007010A patent/KR102208283B1/ko active Active
- 2013-05-30 SI SI201331636T patent/SI2857039T1/sl unknown
-
2014
- 2014-11-25 IL IL235899A patent/IL235899B/en active IP Right Grant
- 2014-11-28 PH PH12014502669A patent/PH12014502669B1/en unknown
- 2014-12-12 ZA ZA2014/09186A patent/ZA201409186B/en unknown
-
2016
- 2016-05-09 JP JP2016094112A patent/JP6406678B2/ja active Active
-
2018
- 2018-01-18 AU AU2018200413A patent/AU2018200413B2/en active Active
- 2018-03-19 JP JP2018051046A patent/JP6620829B2/ja active Active
-
2019
- 2019-06-10 US US16/436,301 patent/US20200148753A1/en not_active Abandoned
- 2019-12-13 CY CY20191101311T patent/CY1122530T1/el unknown
-
2021
- 2021-12-01 US US17/539,926 patent/US20220340646A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091218A1 (es) | Agente terapeutico o agente profilactico para los trastornos cognitivos | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| MX371442B (es) | VARIANTE DE LA REGION FC ESPECIFICA PARA FCyRIIB. | |
| MX2018010733A (es) | Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas. | |
| PE20141672A1 (es) | FORMULACION PARA ANTICUERPO ANTI-alfa4�7 | |
| ES2691070T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| CY1119058T1 (el) | Ενωσεις ιμιδαζοπυρρολιδινονης | |
| MX2020001450A (es) | Composiciones para reducir la inmunosupresion por celulas de tumor. | |
| MX2017008410A (es) | Reduccion selectiva de residuos cisteina en anticuerpos il-17. | |
| BR112014013175A8 (pt) | composições de liberação prolongada baseadas em lipídios anfipáticos e processo para preparar comprimidos de composição de liberação prolongada | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| SA520412669B1 (ar) | تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية | |
| GT201200172A (es) | Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes | |
| PE20150200A1 (es) | Formulacion de anticuerpos | |
| ES2693321T3 (es) | Péptidos antiinflamatorios y composición que comprende los mismos | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| BR112012018947B8 (pt) | anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica | |
| BR112015003591A8 (pt) | Usos de lys-c e métodos para fabricação de um polipeptídeo proteoliticamente processado | |
| BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
| MX2021013913A (es) | Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa. | |
| TR201815173T4 (tr) | Peptit bileşimleri. | |
| BR112014002884A2 (pt) | composição para estimulação ovariana controlada | |
| UY36920A (es) | Formulaciones de aminoácidos de liberación modificada administradas por vía oral | |
| AR092981A1 (es) | Biomarcadores predictivos de la respuesta clinica al acetato de glatiramero | |
| CL2017001592A1 (es) | Complejos radiofarmacéuticos. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |